Business
bioAffinity develops noninvasive diagnostic laboratory tests for early-stage lung cancer and other lung diseases using flow cytometry and machine-learning analysis.
bioAffinity sharpened focus on CyPath Lung, but revenue fell, losses widened, and the Altman-Z screen flagged distress.
The read at a glance✓ Audited against SEC data
- Business mix — Noninvasive lung diagnostic platformNote
- Revenue — Revenue down 34.2%Watch
- CyPath — Testing revenue up 87%OK
- Loss — Net loss widened 64.9%Watch
- FCF — FCF deficit widened 27.9%Watch
- Insiders — 0 purchases / 0 salesNote
- Accounting — Altman-Z -6.60 distressWatch
Where the revenue comes from
Fiscal 2025, as bioAffinity Technologies, Inc. reports it. History and quarterly detail are in the app.
- Laboratory Services$6.2M
- Health Care, Patient Service$5.0M
- Histology Service Fees$1.1M
- Medical Director Fees$68K
- Other Revenues$5K
Leadership changes
From bioAffinity Technologies, Inc.'s own filings, the day they're filed.
- Roby Joyce · Directors · departureeff. 2026-03-05
- Robert Anderson · Directors · departureeff. 2026-03-05
- Roberto Rios · appointmenteff. 2025-08-12
Latest filings
- 8-K · Company announcement2026-09-03
- 8-K · Company announcement2026-09-01
- 8-K · Company announcement2026-08-20
- 8-K · Company announcement2026-08-18
- 8-K · Company announcement2026-08-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about bioAffinity Technologies, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.